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Abstract
Objectives
Definition of the optimal pneumococcal vaccine strategy in HIV-infected adults is still under
evaluation. We aimed to compare immunogenicity and safety of the 13-valent pneumococ-
cal conjugate vaccine (PCV13) versus the 23-valent polysaccharide vaccine (PPSV23) in
HIV-infected adults.
Methods
We performed a pilot, prospective controlled study enrolling HIV-infected pneumococcal
vaccine-naïve outpatients, aged 18–65 years with CD4 counts200 cells/μL. Eligible sub-
jects were recruited into two parallel groups: group 1 (n = 50) received two doses of PCV13
eight weeks apart, and group 2 (n = 50) received one dose of PPSV23, as part of their stan-
dard of care. Anti-pneumococcal capsular polysaccharide immunoglobulin G concentra-
tions were quantified by ELISA at baseline, 8, 24 and 48 weeks. Clinical and viro-
immunological follow-up was performed at the same time points. Unvaccinated, age-
matched HIV-negative adults (n = 100) were also enrolled as baseline controls.
Results
Pre-vaccination specific IgG titers for each pneumococcal antigen did not differ between
study groups but they were constantly lower than those from the HIV-negative controls.
After immunization, significant increases in IgG titers were observed in both study groups at
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each time point compared to baseline, but response to serotype 3 was blunted in group 1.
Antibody titers for each antigen did not differ between study groups at week 48. Overall, the
proportion of subjects achieving seroprotection and seroconversion to all serotypes was
comparable between groups. A marked decrease in IgG levels over time was observed with
both vaccines. No relevant adverse reactions were reported in either group.
Conclusions
In this population with favorable immune profile, no relevant differences were observed in
immunogenicity between PCV13 and PPSV23. Both vaccines were safe and well tolerated.
Trial Registration
ClinicalTrials.gov NCT02123433
Introduction
HIV-infected subjects have an increased risk for invasive pneumococcal diseases (IPD), fre-
quently leading to hospitalization and death [1–4]. Therefore, efforts to reduce the incidence of
IPD in this population constitute a clinically relevant issue even in the era of the highly active
antiretroviral therapy (HAART) [5, 6]. Since the 80’s, the US Centers for Disease Control have
recommended using the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for immu-
nocompromised subjects [7]. As a plain polysaccharide vaccine, PPSV23 does not elicit T cell-
dependent immune responses: the absence of memory B cells reduces the duration of its pro-
tection and re-vaccinations are required also in the immunocompetent host [8]. However,
PPSV23 booster doses have been reported to cause “hyporesponsiveness” [8]. This limitation
makes PPSV23 less suitable for HIV-infected individuals, mainly for those in advanced stages
of immunodeficiency.
Several studies have shown that humoral response to PPSV23 is weaker in HIV-infected
adults compared to an age-matched immunocompetent population [9–11] and that patients
with AIDS fail to be protected [12].
In 2000, protein-conjugated pneumococcal vaccines (PCVs) were licensed and have been
widely adopted for pediatric use: the 7-valent conjugate vaccine formulation (PCV7) has been
demonstrated to greatly decrease the incidence of pneumococcal infections due to vaccine sero-
types [13]. In 2010 the FDA licensed a 13-valent conjugate vaccine formulation (PCV13) that
covers 6 additional serotypes. PCVs induce a T-cell-dependent response that stimulates long-
lived memory cells [14], prevents B-cell depletion and produces high affinity antibodies. PCVs
may also prime the immune system for more rapid and improved responses to booster doses
[15].
Thus, vaccination with PCV could be an optimal primary prophylaxis strategy for HIV-
infected patients. Indeed, in randomized trials of HIV-infected adults PCV7 was shown to
have high efficacy by itself [16] and to be more immunogenic than PPSV23, eliciting a higher
and persistent4-fold increase in antibodies against 6B and 9V serotypes in a larger propor-
tion of HIV patients [17]; moreover, revaccination with PCV7 was reported to elicit a better
serologic response than PPSV23 in HIV-infected adults who had received PPSV23 five or more
years earlier [18].
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To date, international guidelines recommend that HIV+ patients aged19 years, who are
PCV13 naïve should receive a single dose of PCV13. PPSV23 should be given8 weeks after
PCV13; a second dose of PPSV23 should be given 5 years later. For those who previously
received PPSV23, PCV13 should be administered1year after the last PPSV23 dose [19].
To the best of our knowledge a direct comparison of the immunogenicity of PCV13 versus
PPSV23 in HIV-infected adults is still lacking.
The present study aimed to investigate the immunogenicity and safety of administering two
doses of PCV13 to unvaccinated HIV-infected adults and to compare the immunological
response over time with that elicited by PPSV23.
Patients and Methods
Study design
From November 2011 to April 2012, 100 HIV-infected adult outpatients who had never been
vaccinated with any pneumococcal vaccine were prospectively enrolled in two parallel studies,
each performed at two Infectious Diseases Clinical Centers in Central Italy (University Divi-
sion of Infectious Diseases in Siena and Institute of Clinical Infectious Diseases, Catholic Uni-
versity of the Sacred Heart in Rome). The first study was interventional and prospectively
enrolled patients who were assigned to receive the 13-valent pneumococcal vaccine (PCV13
Prevenar131, Wyeth Vaccines), while the second study prospectively enrolled patients who
were receiving their first routine vaccination with PPSV23 (Pneumovax1, Sanofi Pasteur Msd
Spa), which was considered the standard of care based on guidelines viable during the study
period.
For both studies, inclusion criteria were: age18 years and CD4 cell counts200cells/μL.
Exclusion criteria were: age>65 years, pregnancy, non-HIV related immunosuppression, cur-
rent immunomodulatory therapy, any type of previous pneumococcal vaccination, antibiotic
treatment in the previous 7 days and presence of acute infectious diseases.
Three hundred and fifty HIV-infected patients were assessed for eligibility by medical
researchers. A total of 245 patients fully met criteria and were offered to participate by the med-
ical researchers during one of the routine follow up visits, 100 accepted to participate to one of
the two parallel studies. The first group of patients (n = 50) received two doses of PCV13 eight
weeks apart and the second group (n = 50) one dose of PPSV23 as part of their routine care.
A third age-matched group of HIV-negative outpatients (n = 100) was also recruited as con-
trol comparator of pre-immunization IgG antibody levels; control subjects did not receive any
vaccination.
The study was approved by the local Institutional Ethics Committees, considering the
PCV13 vaccination procedure as interventional and experimental. It should be noted that at
the time of the study only PPSV23, not PCV13, was recommended as part of the routine care
vaccinations for HIV-infected adults [20]. All subjects provided written informed consent
before they were enrolled in each study group. Follow-up was completed in May 2013; while
the study ended in November 2013 when outcomes collection was completed.
Patients follow-up
At baseline (day 0, time of first vaccine dose administration,), demographic, clinical and labo-
ratory characteristics were collected by patients interview and using clinical records.
Follow-up visits were scheduled at 8 (time of second PCV13 dose in group 1), 24 and 48
weeks. At each visit peripheral venous blood samples were collected to assess humoral immune
response; CD4+ T cell count and plasma HIV-RNA were also monitored.
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After each vaccine administration, short- (30 minutes), medium- (5 days) and long-term
adverse reactions were monitored.
At baseline, a single peripheral venous blood sample was collected from HIV-negative con-
trols to assess the natural humoral immune response to pneumococcal polysaccharides. Demo-
graphic and clinical variables were also collected.
Determination of anticapsular IgG antibodies against pneumococcal
serotypes
Quantitation of specific IgG levels for 12 serotypes shared by PCV13 and PPSV23 (1, 3, 4, 5,
6B, 7F, 9V, 14, 18C, 19F, 19A and 23F) and for the additional serotype contained only in
PCV13 (6A) was performed on patients’ sera, by an ELISA method, according to the World
Health Organization (WHO) procedure [21]; the protocol was modified by using antigens
from the Staten Serum Institute (SSI Diagnostica, Hillerød, Denmark), in place of ATCC
(American Type Culture Collection, Manassas, VA, US) antigens, as we previously described
[22].
The new human pneumococcal standard reference serum, 007sp, kindly given by Dr. Mus-
tafa Akkoyunlu (US, FDA) [23] and a panel of 12 quality controls (NIBSC cod:12/278; Potters
Bar, Hertfordshire, UK) were employed.
Antigen-specific IgG levels were expressed as geometric mean concentrations (GMCs μg/
mL) for each pneumococcal serotype. The generally used threshold of 0.35μg/mL (accepted by
the WHO for assessment of vaccine efficacy against IPD) [24] and a more conservative thresh-
old of 1 μg/mL (potentially more relevant for long-term protection and previously used in stud-
ies with HIV-infected children)[25, 26] were chosen as cut-offs for defining seroprotection
levels. Moreover, in a recent study individual serotype-specific correlates of protection were
established, except for serotype 5 [27]. We carried out further data analyses also using these
novel serotype-specific seroprotection values.
Seroconversion was defined as a 4-fold post-vaccination increase of the antigen-specific
IgGs over the pre-vaccination levels.
Statistical analysis
At the time of the study design no data were available regarding PCV13 immunogenicity in
HIV positive children or adults. As a consequence, to detect differences in immunological
response to PCV13 versus PPSV23 in HIV-positive adults, sample size estimation was based
on data obtained by vaccination of HIV-infected children with PCV7 and vaccination of HIV-
infected adults with PPSV23. A study by Thanee et al. [28] reported that 85–98% of HIV-
infected children reached an appropriate serotype-specific IgG antibody concentration after
receiving a dose of PCV7. Conversely, a study by Hung at al. [10] estimated that about 40% of
HIV-positive adults had a significant antibody response to PPSV23. On the basis of these data,
we expected to observe a serological response in at least 70% of PCV13-vaccinated HIV-
infected adults. Therefore, based in an expected antibody response in 70% of PCV13-vacci-
nated and 40% of PPSV23-vaccinated HIV-infected patients, we estimated that 50 patients had
to be included in each vaccination group to detect a significant difference between groups at a
probability level of 95% with a power of 81.5%. For baseline characteristics, categorical vari-
ables were compared using a chi-square test or Fisher's exact test, as appropriate. Comparisons
of continuous variables were based on Student’s t-test. The antibody concentrations were log-
transformed to approximate normal distributions. The GMCs were obtained by taking the
antilogarithm of the means of the log-transformed values. Corresponding two-sided 95% con-
fidence intervals (CIs) for the GMCs were constructed by back-transforming the 95% CI for
Immunogenicity of PCV13 and PPSV23 in HIV+ adults
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the mean of logarithmically transformed assay results computed using the Student t distribu-
tion. Student’s t-test was used for testing significance on the log-transformed antibody concen-
trations. General Linear Modeling Repeated Measures ANOVA (GLM-ANOVA) was used to
compare the log-transformed antibody concentrations over the study period within and
between the two vaccinated groups; the Greenhouse-Geisser correction was applied because
the sphericity assumption was violated [29, 30]. Bonferroni method was used for the multiple
comparisons of the mean involved. In the GLM-ANOVA we did not add any covariate. To
compare the proportions of subjects reaching seroprotective levels and subjects who serocon-
verted between the two vaccine groups, Pearson’s chi-square test was used; the Wilson method
was employed to compute the confidence intervals of the proportions. Differences between
groups were considered significant at the conventional p level<0.05. Analyses were performed
using the SPSS software package (version 18.0 Chicago, IL).
Ethics Statement
This study was reviewed and approved by institutional review boards at both of participating
sites (Ethic committee Area Vasta Sud Est, Azienda Ospedaliera Universitaria Senese, Siena,
Italy and Ethic committee of Catholic University of Sacred Heart, Rome, Italy). The project
was approved as two distinct parts: an interventional and experimental study for PCV13 vacci-
nated patients (Eudract number 2011-004518-40 –Protocol code PCV13-HIV2011; Clinical-
Trials.gov n.NCT02123433) and an observational study in PPSV23 vaccinated patients and
HIV negative control (Protocol Code PNEUMO-HIV 2011).
Results
Study population
A total of 100 HIV-positive subjects were enrolled: 50 in group 1 to receive PCV13 and 50 in
group 2 to receive PPSV23 (Fig 1).
Seventy-two percent were males, 92% were Caucasian, 99% received stable antiretroviral
therapy, 88% had HIV-RNA50 copies/mL None had acute infections.
Baseline main characteristics were homogeneous between groups, except for the proportion
of non Caucasian subjects, which was slightly higher in group 1 (Table 1A).
Several pre-immunization characteristics of the HIV+ patients were also comparable with
those of the HIV-negative subjects although the HIV+ subjects were more frequently male and
active smokers and had a lower mean body mass index; they were less frequently alcohol con-
sumers, infected with hepatitis viruses and cohabiting with children (Table 1B).
In group 1, five (10%) patients were lost at follow-up: 4 patients dropped out from the study
for not attending the planned visit at week 8 (the time of PCV13 booster dose administration)
and one more patient refused to complete the study at week 24; one serum sample from a
patient was unavailable at week 24, but it was available at 48 week. Therefore, 45 subjects in
group 1 (90%) completed the follow up, and they were taken into account for the serological
response analysis. All 50 (100%) patients in group 2 completed the planned follow-up, but one
serum sample at week 8 and one serum sample at week 24 were unavailable.
Antibody concentration at baseline
At baseline no significant differences were observed for any PCV13 serotype-specific IgG
GMC between patients who received PCV13 or PPSV23 (Fig 2A). On the other hand, the IgG
GMCs against all serotypes was significantly lower in the HIV-infected patients (the two
groups combined) as compared to the HIV-negative control group (Fig 2B).
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By comparing the two vaccinated groups, no significant difference was observed in seropro-
tection rates at baseline using three different thresholds. When seroprotection levels of HIV-
positive patients were compared with those of HIV-negative subjects using the0.35μg/mL
threshold, significantly fewer HIV-infected patients showed seroprotection levels for serotypes
5, 6B, 9V and 18C. Using the1μg/mL threshold, significantly fewer HIV-infected individuals
compared to HIV-negative subjects showed seroprotective levels for 9 of 13 antigens. Finally,
for clinically validated serotype-specific thresholds of protection, significantly fewer HIV-
infected patients compared to HIV-negative subjects showed seroprotection levels for sero-
types 7F and 9V (S1 Table).
Serological responses within groups
Both vaccines elicited an immune response after the first dose, leading to markedly higher IgG
GMCs to each of the antigens compared to baseline values (with p-values of 0.007 or less). A
significant fluctuation over time (“time effect”) was observed in both groups (with p-values of
0.001 or less). The only exception was represented by the low response to serotype 3 in the
PCV13 group, which was modest at week 8 (vs baseline p = 1.000), and remained constant at
different time points (p = 0.171) (Table 2).
Although antigen 6A was not included in the PPSV23 vaccine, it was assessed in group 2 as
well; as expected no significant variation in antibody levels was observed after immunization.
Overall, in the subsequent months a common descending trend of IgG concentration was
observed in both groups. In group 1, however, the immune responses against serotypes 1, 4, 5,
6B, 14, 19A, 19F and 23F did not change significantly, with IgG levels at week 24 comparable
Fig 1. Flow chart illustrating the entire study population. CONSORT flow diagram.
doi:10.1371/journal.pone.0156523.g001
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Table 1. Characteristics of the study population at enrollment: (A) comparison between the two groups of HIV+ patients and (B) between HIV
+ enrolled patients and HIV- baseline controls.
A
Group 1 (PCV13) n = 50 Group 2 (PPSV23) n = 50 p
Male, n (%) a 34 (68) 38 (76) 0.373
Age, mean (SD) b 43.9 (9,05) 45.6 (10,5) 0.394
Non Caucasian, n (%) a 7 (14) 1 (2) 0.027
Body mass index (Kg/m2), mean (SD) b 23.9 (4.2) 23.2 (3.6) 0.352
Years from HIV diagnosis, mean (SD) b 11.0 (7.6) 12.4 (10.2) 0.434
Years from HAART initiation, mean (SD) b 7.8 (6.11) 10.8 (15.2) 0.197
Risk factor, n (%) a 0.44
Heterosexual 16 (32) 21 (42)
Homo/bisexual 21 (42) 20 (40)
Injecting drug use 7 (14) 7 (14)
Other /Unknown 6 (12) 2 (4)
Nadir CD4 count cell/μL, mean (SD) b 197.9 (132.4) 213.7 (194.3) 0.635
CD4 count, mean (SD) cell/μL b 591.2 (226.5) 639.4 (302.5) 0.371
CD4 cell count category, n (%) a 0.788
200–350 6 (12) 7 (14)
351–500 15 (30) 16 (32)
>500 29 (58) 27 (54)
Viral load 50 copies/μL, n (%) a 42 (84) 46 (92) 0.218
Receipt of HAART, n (%) a 49 (98)§ 50 (100) 0.315
Antiretroviral regimen, n (%) 0.776
PI-based a 32 (64) 34 (68)
NNRTI-based a 11 (22) 12 (24)
Other a 7 (14) 4 (8)
Co-morbidities, n (%)
Diabetes a 2(4) 1(2) 0.558
Cardiovascular disease a 3 (6) 5 (10) 0.461
Neoplasm a 0 (0) 1(2) 0.315
Hepatitis co-infection (HCV or HBV) a 10 (20) 6 (12) 0.275
Recent hospitalization, n (%) (last 12 months) a 2 (4) 4 (8) 0.4
Cohabitation with children, n (%) a 7 (14) 9 (18) 0.585
Age of cohabiting children, n (%) a 0.848
<3 years 1 (14.3) 1 (11.1)
4–16 years 6 (85.7) 8 (88.9)
Past AIDS-deﬁning events, n (%) a 11 (22) 18 (36) 0.123
Smokers*, n (%) a 30 (60) 33 (66) 0.534
Alcohol consumers**, n (%) a 6 (12) 4 (8) 0.505
B
HIV+ (Group 1+2) n = 100 HIV- n = 100 p
Male, n (%) a 72 (72) 52 (52) 0.04
Age, mean (SD) b 44.7 (9.7) 42.4 (13.2) 0.147
Non Caucasian, n (%) a 8 (8) 7 (7) 0.788
Body mass index (Kg/m2), mean (SD) b 23.6 (3.9) 25.1 (5.4) 0.037
Co-morbidities, n (%)
Diabetes a 3 (3) 1 (1) 0.312
Cardiovascular diseasea 8 (8) 13 (13) 0.249
(Continued)
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to those observed at week 8. In group 2, a similar non-significant variation in IgG levels against
serotypes 1, 19A, 19F and 23F was observed. The IgG values against the remaining antigens
showed a significant reduction in both groups at week 24.
Table 1. (Continued)
Neoplasm a 1(1) 5 (5) 0.097
Hepatitis co-infection (HCV or HBV) a 16 (16) 39 (39) <0.001
Recent Hospitalization, n (%) (last 12 months) a 6 (6) 8 (8) 0.579
Cohabitation with children, n (%) a 16 (16) 33 (33) 0.005
Age of cohabiting children, n (%) a 0.121
<3 years 2 (12.5) 11 (33.3)
4–16 years 14 (87.5) 22 (66.7)
Smokers *, n (%) a 63 (63) 30 (30) <0.001
Alcohol consumers**, n (%) a 10 (10) 21 (21) 0.032
Abbreviation SD, Standard Deviation; HBV Hepatitis B Virus; HCV, Hepatitis C Virus; HAART, Highly Active Antiretroviral Therapy; PI, Protease
Inhibitors; NNRTI, Non-Nucleoside Reverse Transcriptase Inhibitors.
a Chi–squared test/ Fisher’s exact test
b Student’s t test
§ One patient started HAART at week 8
* active smoker (100 cigarettes in the last year)
** alcohol consumption  10 Alcholic Unit/week
doi:10.1371/journal.pone.0156523.t001
Fig 2. Baseline geometric mean concentrations (GMCs) of IgGs against the different PCV13
serotypes. (A) Comparison between the 2 groups of HIV-infected patients (n = 50 each group) and (B)
comparison between the total population of HIV-positive subjects (n = 100) and HIV-negative controls
(n = 100). Stars indicate statistically significant differences. Error bars represent the 95% confidence intervals
(95%CIs).
doi:10.1371/journal.pone.0156523.g002
Immunogenicity of PCV13 and PPSV23 in HIV+ adults
PLOS ONE | DOI:10.1371/journal.pone.0156523 June 3, 2016 8 / 18
Table 2. Geometric mean concentration (GMC) and 95% confidence intervals (CIs) of IgGs against pneumococcal serotypes included in PCV13
before (baseline) and after immunization (8, 24 and 48 weeks) with PCV13 or PPSV23 in HIV+ patients. GMC of the HIV-negative control group is also
reported for comparison.
Serotype Time
point
IgG GMC, μg/mL (95% CI)
p p p p
PCV13 Between ﬁrst and
second dose
Within-group
trend over time
PPSV23 Within-group
trend over time
Between PCV13 and
PPSV23 after one
dose
HIV-
negative
1 Baseline 2.09 (1.67–
2.62)
1.95 (1.62–
2.34)
3.01 (2.63–
3.45)
8 weeks 3.30 (2.55–
4.26)
4.66 (3.66–
5.93)
0.02
24 weeks 2.94 (2.36–
3.69)
0.067 <0.001 4.00 (3.18–
5.03)
<0.001
48 weeks 2.65 (2.10–
3.36)
3.29 (2.67–
4.06)
3 Baseline 0.73 (0.57–
0.94)
0.76 (0.61–
0.93)
1.09 (0.96–
1.25)
8 weeks 0.83 (0.64–
1.07)
1.15 (0.94–
1.41)
0.033
24 weeks 0.94 (0.75–
1.18)
0.625 0.171 0.93 (0.76–
1.15)
<0.001
48 weeks 0.81 (0.63–
1.04)
0.91 (0.74–
1.11)
4 Baseline 0.87 (0.68–
1.11)
0.68 (0.54–
0.84)
0.97 (0.83–
1.13)
8 weeks 1.81 (1.34–
2.45)
1.92 (1.49–
2.47)
0.725
24 weeks 1.71(1.32–
2.19)
1.000 <0.001 1,63(1.31–
2.05)
<0.001
48 weeks 1.43 (1.10–
1.84)
1.36 (1.11–
1.67)
5 Baseline 0.78 (0.59–
1.03)
0.77 (0.57–
1.03)
1.04 (0.89–
1.21)
8 weeks 2.51 (1.71–
3.70)
2.61 (1.85–
3.68)
0.664
24 weeks 2.01 (1.45–
2.77)
0.072 <0.001 2.15 (1.56–
2.97)
<0.001
48 weeks 1.82 (1.34–
2.45)
1.65 (1.22–
2.24)
6A Baseline 1.75 (1.40–
2.18)
1.33 (1.03–
1.71)
2.52 (2.09–
3.04)
8 weeks 4.01 (2.84–
5.65)
2.18 (1.69–
2.81)
0.011
24 weeks 3.24 (2.43–
4.33)
0.011 <0.001 1.96 (1.53–
2.52)
0.095
48 weeks 2.61 (1.99–
3.42)
1.72 (1.35–
2.20)
6B Baseline 1.41 (1.05–
1.91)
1.53 (1.12–
2.08)
2.54 (2.14–
3.00)
8 weeks 4.05 (3.00–
5.48)
3.36 (2.56–
4.40)
0.545
24 weeks 3.71 (2.87–
4.77)
1.000 <0.001 2.69 (2.06–
3.51)
<0.001
(Continued)
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Table 2. (Continued)
Serotype Time
point
IgG GMC, μg/mL (95% CI)
p p p p
PCV13 Between ﬁrst and
second dose
Within-group
trend over time
PPSV23 Within-group
trend over time
Between PCV13 and
PPSV23 after one
dose
HIV-
negative
48 weeks 3.11 (2.41–
3.99)
2.55 (2.00–
3.25)
7F Baseline 0.72 (0.55–
0.94)
0.60 (0.48–
0.77)
1.09 (0.92–
1.29)
8 weeks 2.52 (1.82–
3.48)
3.25 (2.35–
4.50)
0.222
24 weeks 1.84 (1.39–
2.44)
0.024 <0.001 2.45 (1.78–
3.37)
<0.001
48 weeks 1.50 (1.13–
2.00)
1.87 (1.38–
2.54)
9V Baseline 0.57 (0.46–
0.71)
0.70 (0.54–
0.92)
1.09 (0.94–
1.27)
8 weeks 2.03 (1.46–
2.81)
2.64 (1.90–
3.66)
0.123
24 weeks 1.68 (1.27–
2.22)
0.033 <0.001 2.28 (1.67–
3.10)
<0.001
48 weeks 1.38 (1.08–
1.75)
1.80 (1.33–
2.44)
14 Baseline 5.59 (4.25–
7.38)
6.69 (5.11–
8.77)
8.49 (7.29–
9.90)
8 weeks 17.25
(12.16–
24.43)
25.37
(18.10–
35.57)
0.113
24 weeks 15.11
(11.12–
20.56)
0.655 <0.001 18.69
(13.33–
26.19)
<0.001
48 weeks 12.43
(9.27–
16.67)
16.33
(11.91–
22.39)
18C Baseline 0.80 (0.63–
1.02)
0.64 (0.49–
0.84)
1.45 (1.25–
1.67)
8 weeks 4.37 (3.16–
6.05)
4.04 (2.84–
5.73)
0.802
24 weeks 3.35 (2.43–
4.61)
0.002 <0.001 3.10 (2.22–
4.33)
<0.001
48 weeks 2.50 (1.88–
3.33)
2.57 (1.89–
3.50)
19A Baseline 3.99 (3.10–
5.15)
4.27 (3.36–
5.43)
6.14(5.27–
7.16)
8 weeks 7.95 (5.97–
10.57)
8.35 (6.05–
11,51)
0.523
24 weeks 7.48 (5.81–
9.65)
1.000 <0.001 7.22 (5.27–
9.90)
<0.001
48 weeks 6.13 (4.70–
7.99)
6.65 (4.87–
9.08)
19F Baseline 4.60 (3.68–
5.75)
4.18 (3.38–
5.18)
7.18 (6.24–
8.26)
8 weeks 8.43 (6.68–
10.65)
6.94 (5.39–
8.94)
0.355
(Continued)
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At week 48, subjects vaccinated with PPSV23 showed no significant changes in IgG levels
against antigens 3, 6B, 14, 19A, 19F and 23F compared to week 24; a similar finding was
observed only for serotypes 3 and 5 with PCV13 in group 1, with a significant decline of IgGs
against all other antigens.
Overall, at week 48 IgGs remained at significantly higher levels compared to the baseline,
except for those against antigen 3 in the PCV13 group (p = 0.346) (Fig 3).
Table 2. (Continued)
Serotype Time
point
IgG GMC, μg/mL (95% CI)
p p p p
PCV13 Between ﬁrst and
second dose
Within-group
trend over time
PPSV23 Within-group
trend over time
Between PCV13 and
PPSV23 after one
dose
HIV-
negative
24 weeks 8.40 (6.78–
10.41)
1.000 <0.001 6.23 (4.91–
7.91)
<0.001
48 weeks 6.60 (5.23–
8.34)
5.65 (4.43–
7.21)
23F Baseline 1.86 (1.42–
2.44)
1.76 (1.38–
2.25)
2.58 (2.20–
3.03)
8 weeks 4.49 (3.24–
6.24)
3.67 (2.69–
5.00)
0.609
24 weeks 4.33 (3.26–
5.74)
1.000 <0.001 3.19 (2.40–
4.25)
<0.001
48 weeks 3.25 (2.47–
4.30)
2.85 (2.18–
3.72)
doi:10.1371/journal.pone.0156523.t002
Fig 3. GMCs of IgGs against S.pneumoniae serotypes at baseline (BL) vs 48 weeks. (A) comparison
within the PCV13 group and (B) within the PPSV23 group. Stars indicate statistically significant differences.
Error bar represents the confidence intervals (CIs 95%).
doi:10.1371/journal.pone.0156523.g003
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Comparison of serological responses between groups
The overall between group analysis revealed no statistically significant difference of the IgG
response to any antigen (S2 Table). The IgG titers changed over time in both groups; specifi-
cally, the IgGs against most antigens varied in a similar manner in both groups at different
time points, resulting in parallel trends with no significant interaction except for IgG titers
against serotypes 1 and 6B, which showed significantly divergent behavior (p = 0.007 and
p = 0.038 respectively). This was because of the higher IgG titers against antigen 1 in the
PPSV23 group at week 8 and the higher IgG titers against antigen 6B in the PCV13 group at
week 24. At week 48, the GMCs of the IgGs against common pneumococcal antigens in the
two vaccine groups were comparable. Note that for most of the antigens, GMC values in both
vaccine groups did not drop below the levels observed in HIV-negative unvaccinated controls;
specifically, the IgGs against antigens 4, 5, 14 and 18C were significantly higher than those
observed in the HIV- negative unvaccinated group, whereas the GMCs against 9V and 7F
were significantly higher than those of the non immunized subjects only in the PPSV23 group
(Fig 4).
No relevant correlation emerged between the CD4 count and the immune response to dif-
ferent pneumococcal serotypes within and between groups. When the population was stratified
by the CD4 cell count (200–350 cell/μL, 351–500 cell/μL, or>500 cell/μL) and by the plasma
viral load (HIV-1 RNA>50 and50 copies /mL) no relevant difference emerged.
Seroprotection and seroconversion of IgG levels during the follow-up
After vaccination, the proportion of responders using different cut-off thresholds was similar
in both groups, albeit responders to serotype 3 at weeks 8 and 48, were significantly fewer in
the PCV13 group when using both thresholds of1 μg/mL and of 0.35 μg/mL, respectively
(Fig 5A). Percentages of seroconverters varied for each antigen in both groups;<20% of sero-
converters was observed for antigens 1, 3, 19A and 19F at each time point. However, overall
seroconversion rates were similar in both vaccine groups: a significant difference in serocon-
vertion rates was observed only for antigen 6B at week 24 when subjects immunized with
PCV13 showed a significantly higher percentage of seroconvertion than those immunized with
PPSV23 (Fig 5B).
Fig 4. Geometric mean concentration of vaccinated groups, PCV13 and PPSV23, at 48 weeks compared to level
of unvaccinated HIV-negative control group. Stars indicate significant differences between each HIV vaccinated
group (PCV13 and PPSV23) and the HIV-negative unvaccinated control group. Error bar represents the confidence
intervals (CIs 95%).
doi:10.1371/journal.pone.0156523.g004
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Safety
Both vaccinations were well tolerated by all subjects: no severe short-, medium- or long-term
local or systemic reactions were reported.
Two patients receiving PCV13 reported mild fatigue, one immediately after injection and
the other the day after, both lasting a few hours; another patient reported transient itching at
the injection site. However, there was no statistical difference between the groups in terms of
adverse reactions.
After the second PCV13 dose at week 8 no additional adverse events were reported.
Clinical follow-up
No infection due to S. pneumoniae occurred during the follow-up in any of the 100 HIV-
infected patients.
At 8 weeks, the proportion of individuals in the PCV13 group who had an HIV load50
copies/μL was significantly lower than that of the PPSV23 patients (84.8% vs 98.0% p = 0.027).
Overall, the CD4 range remained constant and comparable at the different time points between
groups and no statistically significant frequency in viral blips (single measures of HIV RNA
51–500 copies/mL followed by HIV-RNA<50 copies/mL at the subsequent measure) was
observed (15.6% in PCV13 vs 8.3% in PPSV23, p = 0.281).
Discussion
While PPSV23 has been for many years a recommended pneumococcal vaccine for HIV-
infected patients, PCV13 has only recently been approved for use in immunocompromised
subjects [19] and data regarding its effectiveness in HIV+ adults are still scanty. Only two
recent studies evaluated PCV13 in HIV+ adults and neither directly compared it with PPSV23.
Glesby et al. evaluated three administrations of PCV13 in subjects previously vaccinated with
PPSV23 [31] and Bhorat et al. evaluated three administrations of PCV13 followed by a single
dose of PPSV23 in pediatric and adult subjects who were naïve to the pneumococcal vaccina-
tion [32].
Overall, in our population, which mainly consisted of virologically suppressed and immu-
nologically stable HIV+ patients, both vaccines showed comparable immunogenicity at the
end of the follow-up (48 weeks) and the two doses of PCV13 were as safe and well tolerated as
the single dose of PPSV23. According to international guidelines, a single dose of PCV13 is
now recommended in HIV+ patients aged19 years who are PCV13 naïve [19]; the European
Medicine Agency recommends at least 1 dose of PCV13 for immunocompromised patients
and up to 4 doses for subjects with severe immunodepression (e.g. subjects with
Fig 5. Seroprotection and seroconversion rates. (A) Proportion of responders who achieved IgG
levels 0.35μg/mL and1μg/mL or serotype-specific clinically validated thresholds (correlates of protection)
at the different follow-up time points (a clinical correlate of protection for serotype 5 is unavailable). (B)
Percentage of patients who reached IgG seroconversion defined as a 4-fold rise from baseline antibody
levels at the different follow-up time points. Stars indicate a significant difference. Error bar represents the
confidence intervals (CIs 95%).
doi:10.1371/journal.pone.0156523.g005
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haematopoietic stem cell transplants) [33]. The administration of multiple PCV13 doses in the
two aforementioned trials in HIV+ adults [31, 32] revealed modest increases in IgG GMCs
after the second and third dose in contrast with the relevant increase observed after the first
dose.
Similar to our study, both previous studies analyzed an HIV+ population with an overall
favorable viro-immunological profile (CD4 count200 cells/μL and viral load<50 copies/
mL). Also, in our study no significant increase in IgGs was observed after the second dose of
PCV13 (as compared to after the first dose). These current findings suggest that a single dose
of PCV13 should be given in HIV-infected adults with a stable CD4 count200 cells/μL and a
viral load<50 copies/mL. Nonetheless, future studies should analyze patients with lower CD4
counts and should include a longer follow up in order to investigate the maintenance of IgG
levels over time with single or multiple doses of PCV13.
Another relevant issue is the possible different response to different pneumococcal sero-
types in relation to the single serotype itself or to the type of vaccine.
When PCV13 was compared with PPSV23 in HIV negative adults [34], most of the PCV13
serotypes elicited a statistically significantly higher response, with the exception of serotypes 3,
7F and 14. In particular, serotype 3 was reported to be less immunogenic, with the potential
consequence of a lower long-term efficacy of PCV13 against pneumococcal disease caused by
this serotype [35].
In our study, although no differences were observed in response to serotypes 7F and 14,
PCV13 showed a lower immunogenicity for serotype 3, giving rise to a modest response at
week 8; consistently, week 48 IgG levels did not differ from those at pre-vaccination. However,
similar low percentages of seroconverters (<20%) were observed for serotype 3 in both study
groups, similarly as for serotypes 1, 19A and 19F. Thus, substantially lower immunogenicity of
these antigens can be presumed, regardless of vaccine type, in this population.
In terms of seroprotection, we found that the percentage of responders to serotype 3 was sig-
nificantly lower in the PCV13 group at week 8 and 48 using the threshold of1 μg/mL and of
0.35 μg/mL, respectively; conversely, when the serotype 3-specific clinically validated thresh-
old was analyzed, the proportion of responders was markedly below 20% in both groups, with
no significant difference. A randomized trial that compared the immunogenicity of PPSV23
with a pentavalent conjugate pneumococcal vaccine composed of serotypes 6B, 14, 18C, 19F
and 23F linked to CRM197 carrier protein in HIV positive patients showed that a similar anti-
body response was elicited by the two vaccines [36].
In a different study, which focused on HIV-infected subjects with CD4 200 cells/μL, the
antibody concentrations between PCV7 and PPSV23 were not dramatically different for sero-
types 4, 6B, 9V, 14 and 23F [37].
Our data consistently show no differences between the two vaccinated groups regarding the
IgG titers of any of these antigens. A better response in terms of seroconversion against sero-
type 6B and 9V was previously reported in a randomized trial of HIV-infected adults vacci-
nated with PCV7 versus PPSV23 [17]. In our patients, the proportion of seroconverters in the
PCV13 group significantly exceeded that of the PPSV23 group only for serotype 6B at week 24.
On the contrary, significantly higher IgG titers against serotype 1 were observed in the PPSV23
as compared to the PCV13 group at week 8 but not at subsequent time points when the PCV13
group had received the second dose. These observations may suggest that a variably combined
PCV13 and PPSV23 vaccine strategy could help overcome the low immunogenicity of some
antigens in the respective vaccines.
Our study has some limitations. First of all, the small sample size. Indeed, the study was suf-
ficiently powered only to demonstrate major differences in antibody responses between the
two vaccine schedules: it was not designed as a non inferiority trial and further larger non
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inferiority studies will be needed. Second, the study was not randomized, although the two vac-
cine groups showed very similar general, immunological and exposure risk characteristics at
baseline. Third, the study population showed a good and stable viro-immunological status,
therefore our findings cannot be extrapolated to HIV-infected patients with more severe
immune deficiency, where a different scenario is expected. Finally, a longer follow-up is
required to analyze the long-term serological response, the immunological memory and their
correlation with clinical events.
Nonetheless, this study represents the first direct comparison of the PCV13 and PPSV23
vaccine response in HIV-infected adults. With a one-year longitudinal follow-up study, we
showed that results of PCV13 and PPSV23 comparisons obtained in HIV-negative adults [34]
cannot be fully applied to the HIV-positive population.
In conclusion, we did not observe any relevant differences in immunological responses to
PCV13 and PPSV23 vaccination after 1 year in HIV-infected adults. Some divergence was
noted at some time points, with specific serotypes and a marked “time effect” was noted, with a
progressive reduction of IgG levels over time in both vaccination groups. The property of
PCV13 to elicit immunological memory could hypothetically reveal an advantage in the longer
term, but this still requires demonstration in the HIV-infected population; on the other hand,
the response to PPSV23 might be slightly better for certain serotypes and it obviously offers a
broader serotype coverage.
Further studies are needed to evaluate long term efficacy in both groups and to establish the
optimal pneumococcal vaccine strategy in HIV positive adults with different viro-immunologi-
cal profiles.
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